Humanization strategy of the heavy chain variable region
SmocMab®全人源抗体小鼠
SmocMab®全人源抗体小鼠采用大片段基因序列替换技术，将人类抗体可变区基因库整合到C57BL/6小鼠的内源位点，在可变区全人源化的基础上保留了近似野生型的健全免疫应答能力，提供了更广泛的免疫反应谱，可成功生产大量高亲和力的全人源化抗体，助力治疗性抗体新药研发。
人源化策略
Humanization strategy of the kappa light chain variable region
免疫检测
Normal B cell development lays a solid foundation for antibody production.
全人抗体库多样性
相关案例
Fig. Detection of antibody titer in serum after 1st or 2nd boost in SmocMab and C57BL/6.
Fig. Detection of antibody titer in serum after three antigen immunizations in SmocMab(A) and C57BL/6(B).
Fig. Detection of antibody titer in serum after three antigen immunizations in SmocMab and C57BL/6.
Fig. Detection of antibody titer in serum after three antigen immunizations in Smocmab and C57BL/6
Fig. Detection of antibody titer in serum after three antigen immunizations in SmocmabTM(A) and C57BL/6(B).
Fig. C57 mice were injected with different form of F-Luc mRNA intramuscularly. Eight hours after transfection, Mice received Self-Amplifying LNP-delivered F-Luc mRNA exhibited high and prolonged protein expression.
Fig. Detection of antibody titer in serum after three antigen immunizations in protein or mRNA-LNP immunization.
